Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. DOVA today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the 37^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 3:00 p.m. ET in San Francisco, CA.

A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.

About Dova Pharmaceuticals, Inc.

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova's proprietary pipeline includes one commercial product, DOPTELET^®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Contacts

Mark W. Hahn

(919) 338-7936

mhahn@dova.com

Westwicke Partners

John Woolford

(443) 213-0506

john.woolford@westwicke.com